secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0000950170-25-040249
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical to manufacture PermeaDerm; revenue share rises to 60%
-------------------------------------------------------------------

- 10-year contract manufacturing agreement for PermeaDerm at AVITA's Ventura, CA facility.
- Revenue share for AVITA increases to 60% after manufacturing costs (was 50/50).
- Stedical eligible for milestone payments tied to AVITA's achievement of sales targets.
- Exclusive distribution agreement term extended to ten years from March 17, 2025.
- PermeaDerm is FDA-cleared biosynthetic wound matrix; eligible for U.S. reimbursement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000095017025040249/0000950170-25-040249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000095017025040249/rcel-20250317.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-040249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer